Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• WuTHsiueEHLeeJHLinCCYangJCNew data on clinical decisions in NSCLC patients with uncommon EGFR mutationsExpert Rev Respir Med2016111515527927060
   PubMed Web of Science ®Google Scholar
• ImprotaGPettinatoAGieriSEpidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: a case report combined with a review of the literature and investigation of clinical significanceOncol Lett201511139339826870223
   PubMed Web of Science ®Google Scholar
• KobayashiYMitsudomiTNot all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategyCancer Sci201610791179118627323238
   PubMed Web of Science ®Google Scholar
• YangJCSequistLVGeaterSLClinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6Lancet Oncol201516783083826051236
   PubMed Web of Science ®Google Scholar
• EttingerDSWoodDEAkerleyWNCCN guidelines insights: non-small cell lung cancer, version 4.2016J Natl Compr Canc Netw201614325526426957612
   PubMed Web of Science ®Google Scholar
• ZhouCWuYChenGBEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancerJ Clin Oncol201533192197220426014294
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPOverall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Ann Oncol20102191804180920150572
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• SandlerAYiJDahlbergSTreatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancerJ Thorac Oncol2010591416142320686429
   PubMed Web of Science ®Google Scholar
• ReckMHagiwaraKHanBctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS StudyJ Thorac Oncol201611101682168927468938
   PubMed Web of Science ®Google Scholar
• SchwaederleMCPatelSPHusainHUtility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinomaClin Cancer Res201723175101511128539465
   PubMed Web of Science ®Google Scholar
• HellmannMDRevaBYuHClinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinibJ Thorac Oncol2014910e73e7425521405
   PubMed Web of Science ®Google Scholar
• ArcilaMENafaKChaftJEEGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristicsMol Cancer Ther201312222022923371856
   PubMed Web of Science ®Google Scholar
• KuiperJLHashemiSMSThunnissenENon-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatmentBr J Cancer2016115121504151227875527
   PubMed Web of Science ®Google Scholar
• Beau-FallerMPrimNRuppertAMRare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10117 patients: a multicentre observational study by the French ERMETIC-IFCT networkAnn Oncol201425112613124285021
   PubMed Web of Science ®Google Scholar
• TanizakiJBannoETogashiYCase report: durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutationLung Cancer2016101111527794398
   PubMed Web of Science ®Google Scholar
• KanchaRKvon BubnoffNPeschelCDuysterJFunctional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapyClin Cancer Res200915246046719147750
   PubMed Web of Science ®Google Scholar
• BannoETogashiYNakamuraYSensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: what is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Cancer Sci201610781134114027240419
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKMaemondoMNorth-East Japan Study GroupUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol2013241545922967997
   PubMed Web of Science ®Google Scholar
• SetoTKatoTNishioMErlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyLancet Oncol201415111236124425175099
   PubMed Web of Science ®Google Scholar
• OtsukaKHataAEGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancerCancer Chemother Pharmacol201576483584126349474
   PubMed Web of Science ®Google Scholar
• PengYCuiHLiuZApatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case reportOnco Targets Ther2017102289229528490886
   PubMed Web of Science ®Google Scholar
• NovelloSBarlesiFCalifanoRMetastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201627Suppl 5v1v2727664245
   PubMed Web of Science ®Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
   PubMed Web of Science ®Google Scholar
• RussoAFranchinaTRicciardiGRRAdamoVRapid acquisition of T790M mutation after treatment with afatinib in an NSCLC patient harboring EGFR Exon 20 S768I mutationJ Thorac Oncol2017121e6e827988103
   PubMed Web of Science ®Google Scholar
• LongoLMengoliMCBertoliniFBettelliSManfrediniSRossiGSynchronous occurrence of squamous-cell carcinoma “transformation” and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinomaLung Cancer2017103242628024692
   PubMed Web of Science ®Google Scholar
• MasagoKFujitaSIrisaKGood clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; Codon 768 AGC > ATC in Exon 20 (S768I)Jpn J Clin Oncol201040111105110920522446
   PubMed Web of Science ®Google Scholar
• Lund-IversenMKleinbergLFjellbirkelandLHellandABrustugunOTClinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutationsJ Thorac Oncol2012791471147322895145
   PubMed Web of Science ®Google Scholar
• WeberBHagerHSorensenBSEGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancerLung Cancer201483222423024388704
   PubMed Web of Science ®Google Scholar
• PallanLTanierePKohPRare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two casesJ Thorac Oncol2014910e75
   PubMed Web of Science ®Google Scholar
• ChiuCHYangCTShihJYEpidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adeno-carcinomas with G719X/L861Q/S768I mutationsJ Thorac Oncol201510579379925668120
   PubMed Web of Science ®Google Scholar
• HeigenerDFSchumannCSebastianMAfatinib Compassionate Use Consortium (ACUC)Afatinib in non-small cell lung cancer harboring uncommon EGFR mutations pretreated with reversible EGFR inhibitorsOncologist201520101167117426354527
   PubMed Web of Science ®Google Scholar
• YangXChenHZhangHEffectiveness of tyrosine kinase inhibitors on uncommon epidermal growth factor receptor mutations in non-small cell lung cancerZhongguo Fei Ai Za Zhi2015188493499 Chinese26302346
   PubMedGoogle Scholar
• LeventakosKKippBRRumillaKMWintersJLYiESMansfieldASS768I mutation in EGFR in patients with lung cancerJ Thorac Oncol201611101798180127211795
   PubMed Web of Science ®Google Scholar
• KlughammerBBruggerWCappuzzoFExamining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutationsJ Thorac Oncol201611454555526773740
   PubMed Web of Science ®Google Scholar
• ChengGSongZChenDClinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutationsOnco Targets Ther201694181418627468240
   PubMed Web of Science ®Google Scholar
• KobayashiHWakudaKTakahashiTEffectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosisRespirol Case Rep201646e0019728031832
   PubMedGoogle Scholar
• ZhangYWangZHaoXClinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutationsChin J Cancer Res2017291182428373750
   PubMed Web of Science ®Google Scholar
• ZhuXBaiQLuYResponse to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I: a retrospective analysis and literature reviewTarget Oncol2017121818827538584
   PubMed Web of Science ®Google Scholar